Selpercatinib demonstrated a highly statistically significant and clinically meaningful improvement in reducing the risk of disease recurrence or death Results from the LIBRETTO-432 trial build on ...
Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in patients with early-stage (II-IIIA) rearranged during transfection (RET) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results